A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
Actinic Keratosis
DRUG: PEP005 Gel|DRUG: Vehicle gel
Patients With Complete Clearance of Actinic Keratosis (AK) Lesions., Complete clearance rate of actinic keratosis (AK) lesions, defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area., 57 days
Patients With Partial Clearance of Actinic Keratosis (AK), Patients with partial clearance defined as â‰¥ 75% reduction in the number of actinic keratosis (AK) lesions identified at baseline in the treatment area, baseline and 57 days
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.